Lista de obras - Franco Odicino - Dominio Público Uruguay

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

artículo científico publicado en 2008

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience

artículo científico publicado en 1991

Cancer in women.

artículo científico publicado en 2003

Carcinoma of the cervix uteri.

artículo científico publicado en 2003

Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

artículo científico publicado en 2006

Carcinoma of the corpus uteri.

artículo científico publicado en 2003

Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

artículo científico publicado en 2006

Carcinoma of the vagina.

artículo científico publicado en 2003

Carcinoma of the vulva

artículo científico publicado en 2003

Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

artículo científico publicado en 2006

Cervical cancer staging.

artículo científico publicado en 2003

Consolidation therapies revisited: weekly paclitaxel

scientific article published on 01 November 2003

Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients

article

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

artículo científico publicado en 2011

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy

article

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

artículo científico publicado en 2015

Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study

artículo científico publicado en 2006

Five-year follow-up of placental involution after abdominal pregnancy

artículo científico publicado en 2003

Gestational trophoblastic diseases.

artículo científico publicado en 2003

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study

artículo científico publicado en 2016

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization

artículo científico publicado en 2007

History of the FIGO cancer staging system.

artículo científico publicado en 2008

Hormone replacement therapy in breast cancer

artículo científico publicado en 1993

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome

artículo científico publicado en 2012

Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

artículo científico publicado en 2016

Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology

artículo científico publicado en 2010

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence

artículo científico publicado en 2009

Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology.

artículo científico publicado en 2014

Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity.

artículo científico publicado en 2003

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition

scientific article published on 10 October 2016

New development of the FIGO staging system

scientific article published on 29 August 2007

Optimizing gemcitabine regimens in ovarian cancer.

artículo científico publicado en 2006

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

artículo científico publicado en 2009

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium

artículo científico publicado en 2004

Recurrent ovarian carcinoma: Salvage treatment with platinum in patients responding to first-line platinum-based regimens

artículo científico publicado en 1993

Revised FIGO staging for carcinoma of the cervix

artículo científico publicado en 2009

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

artículo científico publicado en 2011

Staging of gynecologic malignancies

scientific article published on 01 August 2001

Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma

artículo científico publicado en 2020

The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord ovest (GONO)

scientific article published on 01 January 1994

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

artículo científico publicado en 2010

Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?

artículo científico publicado en 2007

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

scientific article published on 17 October 2019

Lista de obras de Franco Odicino

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience

Cancer in women.

Carcinoma of the cervix uteri.

Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Carcinoma of the corpus uteri.

Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Carcinoma of the vagina.

Carcinoma of the vulva

Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Cervical cancer staging.

Consolidation therapies revisited: weekly paclitaxel

Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study

Five-year follow-up of placental involution after abdominal pregnancy

Gestational trophoblastic diseases.

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization

History of the FIGO cancer staging system.

Hormone replacement therapy in breast cancer

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome

Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence

Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology.

Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition

New development of the FIGO staging system

Optimizing gemcitabine regimens in ovarian cancer.

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium

Recurrent ovarian carcinoma: Salvage treatment with platinum in patients responding to first-line platinum-based regimens

Revised FIGO staging for carcinoma of the cervix

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

Staging of gynecologic malignancies

Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma

The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord ovest (GONO)

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy